急性白血病细胞中CD19的表达

目的观察CD19在急性白血病(AL)中的表达与分布,为白血病的诊断、鉴别以及导向治疗提供依据.方法采用27个荧光直标单克隆抗体(单抗)及CD45/SSC双参数设门多色流式细胞术对321例AL细胞进行免疫诊断和分型,并对CD19在各类型AL细胞中的表达情况进行分析.结果在116例B细胞系急性淋巴细胞性白血病(ALL)患者中,CD19的阳性率(99.1%)明显高于B细胞系其它相关性抗原的阳性率;CD19在17例含B细胞系成分的杂合型白血病(HAL)中全部表达,而在29例T细胞系ALL和7例T/My HAL则均无表达;在152例急性髓系白血病(AML)中,仅11例(7.2%)CD19阳性,明显低于其在B细胞系ALL中的阳性率(P=0.001);CD22在B/My HAL的阳性率(12/15,80.0%)明显高于CD19 -AML(0/11,0%,P＜0.001).结论 CD19对B系ALL细胞的特异性较好,敏感性较高,是诊断B细胞系ALL较为可靠的表面标记,也可作为导向治疗B细胞系ALL的理想靶点.

Expression of CD19 in 321 cases of acute leukemia

Objective To investigate the expression and distribution of CD19 on acute leukemia(AL) cel ls and its significance. MethodsUsing a panel of 27 fluorochrome directly labeled monoclonal antibodies, samples from 321 AL patients were analy zed by CD45/SSC double parameters and multi-color flow cytometry to determine t he expression of CD19. ResultsIn 116 cases of B lineage ac ute lymphoblastic leukemia (ALL), the positive rate of CD19 (99.1%) was signific antly higher than that of the other B cell related antigens. CD19 was expressed on all 17 cases of B/myeloid (My) and B/T lineage hybrid acute leukemia (HAL), b ut was not expressed on 29 cases of T lineage leukemia and 7 cases of T/My HAL. In 152 cases of acute myeloid leukemia (AML), only 11 cases expressed CD19. The positive rate of CD19 (7.2%) on AML was significantly lower than that on B line age ALL (P=0 001). The positive rate of CD22 (12/15,80.0%) on B/My HAL was higher than that (0/11,0%,P<0 001) on CD19 +-AML. ConclusionThe sensitivity and specificity of CD19 on B lineage ALL are high, CD19 is continuously and stably expressed on all stages of B lineage differentiation. I t might be a reliable cell membrane marker for diagnosing B lineage ALL and an ideal target for antibody-targeting treatment of leukemia as well.